| Patents for C12N 15 - Mutation or genetic engineering; Dna or rna concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor (402,210) |
|---|
| 02/20/2003 | CA2456390A1 Fusion proteins for insect control |
| 02/20/2003 | CA2456369A1 Proteins associated with cell growth, differentiation, and death |
| 02/20/2003 | CA2456311A1 Wheat plants having increased resistance to imidazolinone herbicides |
| 02/20/2003 | CA2456287A1 Anti-idiotypic antibodies of hla class i molecules and the use thereof in the preparation of compositions that are designed to inhibit vascular activation |
| 02/20/2003 | CA2456223A1 Regulation of the apj receptor for use in the treatment or prophylaxis of cardiac diseases |
| 02/20/2003 | CA2456222A1 Method for producing a marker-free mutated target organism and plasmid vectors suitable for the same |
| 02/20/2003 | CA2456175A1 Benzoquinone ansamycins |
| 02/20/2003 | CA2456010A1 Phosphorylated histone h2b as an apoptosis marker |
| 02/20/2003 | CA2455512A1 Wheat plants having increased resistance to imidazolinone herbicides |
| 02/20/2003 | CA2455498A1 Antisense modulation of apolipoprotein(a) expression |
| 02/20/2003 | CA2455430A1 Sugar and lipid metabolism regulators in plants iii |
| 02/20/2003 | CA2455424A1 Compositions and methods for the prevention and treatment of huntington's disease |
| 02/20/2003 | CA2455336A1 Peptides that bind to atherosclerotic lesions |
| 02/20/2003 | CA2455200A1 Starch modification |
| 02/20/2003 | CA2455161A1 Method and nucleic acids for the analysis of colon cancer |
| 02/20/2003 | CA2454686A1 Use of xylene monooxygenase for the oxidation of substituted monocyclic aromatic compounds |
| 02/20/2003 | CA2454648A1 Irinotecan for treatment of cancer |
| 02/20/2003 | CA2454643A1 Methods for the treatment of cancer with irinotecan based on cyp3a5 |
| 02/20/2003 | CA2454640A1 Methods for treatment of cancer using irinotecan based on ugt1a1 |
| 02/20/2003 | CA2454637A1 Use of irinotecan for improved treatment of cancer based on mdr1 |
| 02/20/2003 | CA2454627A1 Methods for improved treatment of cancer with irinotecan based on mrp1 |
| 02/20/2003 | CA2454519A1 Hprp4s as modifiers of the p53 pathway and methods of use |
| 02/20/2003 | CA2454514A1 Sphks as modifiers of the p53 pathway and methods of use |
| 02/20/2003 | CA2453995A1 Tacis and br3 polypeptides and uses thereof |
| 02/20/2003 | CA2453914A1 Rapid and specific detection of campylobacter |
| 02/20/2003 | CA2453913A1 Method for identifying substances which positively influence inflammatory conditions |
| 02/20/2003 | CA2453327A1 Stress-associated genetic products from ashbya gossypii |
| 02/20/2003 | CA2453248A1 Compositions and methods for the therapy and diagnosis of breast cancer |
| 02/20/2003 | CA2452488A1 Electrodes coated with treating agent and uses thereof |
| 02/20/2003 | CA2451919A1 Nucleic acids, polypeptides, single nucleotide polymorphisms and methods of use thereof |
| 02/20/2003 | CA2450780A1 Novel recombinant gene expression method by stop codon suppression |
| 02/20/2003 | CA2430642A1 Plant seed specific promoters |
| 02/20/2003 | CA2425040A1 Novel rice gene controlling tolerance to salt stress |
| 02/19/2003 | WO2004015060A2 Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
| 02/19/2003 | WO2002016574A2 Method for identifying peptides that can be specifically cleaved and the use of peptide sequences of this type |
| 02/19/2003 | EP1284423A2 Adrenic acid (delta 7,10,13,16 docosatetraenoic acid ) receptor and uses thereof |
| 02/19/2003 | EP1284298A2 Identification and use of molecules implicated in pain |
| 02/19/2003 | EP1284297A2 Identification and use of molecules implicated in pain |
| 02/19/2003 | EP1284294A1 Novel recombinant adenovirus vector with relieved side effects |
| 02/19/2003 | EP1284292A2 Human B-cell Translocation Gene-3 |
| 02/19/2003 | EP1284291A1 Human pgc-1 promoter |
| 02/19/2003 | EP1284290A1 Increase of the expression levels of factor VIII by insertion of spliceable nucleotide sequences into factor VIII cDNA |
| 02/19/2003 | EP1284287A1 Method of preparing virus vector |
| 02/19/2003 | EP1284286A1 Alpha-isomaltosyltransferase, process for producing the same and use thereof |
| 02/19/2003 | EP1284285A2 Method for collecting cells in M phase or G1 phase and method for nuclear transplantation using the cells |
| 02/19/2003 | EP1283911A2 Method for detecting and characterising activity of proteins involved in lesion and dna repair |
| 02/19/2003 | EP1283908A1 Methods of obtaining active antisense compounds |
| 02/19/2003 | EP1283906A1 Epigenetic sequences for esophageal adenocarcinoma |
| 02/19/2003 | EP1283905A2 Diagnosis of diseases associated with the cell cycle |
| 02/19/2003 | EP1283903A1 Drug screening systems and assays |
| 02/19/2003 | EP1283895A2 Retroviral vectors comprising an enhanced 3' transcription termination structure |
| 02/19/2003 | EP1283894A1 Use of baculovirus vectors in gene therapy |
| 02/19/2003 | EP1283893A2 Gene regulatory region that promotes root-specific transcription and its uses |
| 02/19/2003 | EP1283892A2 Gene regulatory region that promotes early seed-specific transcription |
| 02/19/2003 | EP1283891A1 Plants containing a cytosolic acetyl coa-carboxylase nucleic acid |
| 02/19/2003 | EP1283890A1 Hydrogen peroxide lyase regulatory region |
| 02/19/2003 | EP1283889A1 Mutated eukariotic translation initiation factor 2 alpha kinase 3, eif2ak3, in patients with neonatal insulin-dependent diabetes and multiple epiphyseal dysplasia (wolcott-rallison syndrome) |
| 02/19/2003 | EP1283888A2 Fructosyltransferases (inulosucrase and levansucrase) from lactobacillus reuteri |
| 02/19/2003 | EP1283887A1 Chimeric arterivirus-like particles |
| 02/19/2003 | EP1283886A2 Intracellular signaling proteins |
| 02/19/2003 | EP1283885A2 Compositions and methods for the therapy and diagnosis of breast cancer |
| 02/19/2003 | EP1283884A2 Production of adenine nucleotide translocator (ant), novel ant ligands and screening assays therefor |
| 02/19/2003 | EP1283883A1 Treatment of cancer and neurological diseases |
| 02/19/2003 | EP1283882A1 Ssa-56kda polypeptide and its fragments and polynucleotides encoding said polypeptides and therapeutic uses |
| 02/19/2003 | EP1283881A2 Immobilized nucleic acids and uses thereof |
| 02/19/2003 | EP1283880A1 Antiviral antisense therapy |
| 02/19/2003 | EP1283878A2 Receptor-based interaction trap |
| 02/19/2003 | EP1283877A2 Gene recombination and hybrid protein development |
| 02/19/2003 | EP1283876A2 Beta-galactosidase isolated from bifidobacterium |
| 02/19/2003 | EP1283875A1 Improved nucleic acid modifying enzymes |
| 02/19/2003 | EP1283874A2 Novel deoxynucleoside kinase enzyme variants |
| 02/19/2003 | EP1283870A1 Novel cell systems having specific interaction of peptide binding pairs |
| 02/19/2003 | EP1283869A2 Novel bee venom polypeptides and methods of use thereof |
| 02/19/2003 | EP1283868A2 Isolated gum operon from xyllela fastidiosa, isolated nucleic acid molecules therefrom, and uses thereof |
| 02/19/2003 | EP1283849A2 Human receptor proteins; related reagents and methods |
| 02/19/2003 | EP1283848A2 Protein complexes and assays for screening anti-cancer agents |
| 02/19/2003 | EP1283847A1 Pancreatic progenitor 1 gene and its uses |
| 02/19/2003 | EP1283721A1 Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders |
| 02/19/2003 | EP1283718A2 Porcine reproductive and respiratory syndrome virus (prrsv) recombinant avipoxvirus vaccine |
| 02/19/2003 | EP1283716A1 Vaccine comprising a tick cement protein |
| 02/19/2003 | EP1283675A1 Methods of modulating the activity of mura |
| 02/19/2003 | EP1283668A1 Nucleic acids that control plant development |
| 02/19/2003 | EP1206561B1 Method for production of proteinaceous substances |
| 02/19/2003 | EP1092046A4 Methods, compositions and apparatus for making nucleic acid molecules having a selected affinity to a target molecule |
| 02/19/2003 | EP1056777A4 Ligand receptors and uses therefor |
| 02/19/2003 | EP0871764B1 Screening method |
| 02/19/2003 | EP0758381B1 Biologically active eph family ligands |
| 02/19/2003 | EP0699237B1 Anti-egfr single-chain fvs and anti-egfr antibodies |
| 02/19/2003 | CN1398301A Process for labeling nucleic acid |
| 02/19/2003 | CN1398300A Novel elongase gene and method for producing multiple-unsaturated fatty acids |
| 02/19/2003 | CN1398299A BZIP type transcripton factors regulating expression of rice storage protein |
| 02/19/2003 | CN1398298A Non-endogenous, constitutively activated human G protein-coupled receptors |
| 02/19/2003 | CN1398297A Recombinant flaviviruses and methods of use thereof |
| 02/19/2003 | CN1398187A Method and compsns. for treating liver cell cancer |
| 02/19/2003 | CN1397647A Process for transforming antibacterial peptide AD gene by yeast fermentation |
| 02/19/2003 | CN1397646A Process for cloning myocardial cell, heart tissue and heart |
| 02/19/2003 | CN1397643A Method for expressing modified human alpha antitrypsin gene in sheep's mammar gland |
| 02/19/2003 | CN1397642A Recombinant herpesvirus carrying antivascular and antiendothelial cell factors fusion gene |
| 02/19/2003 | CN1397641A Virus reproduced in tumor cell for expressing angiogenesis suppressor factor and its configuring process |
| 02/19/2003 | CN1397639A Cholera vibrio strain |